AI for Regulated Life Sciences

GxMind

Trustworthy AI Platform for Life Sciences

A next-generation AI platform built for regulated pharmaceutical and life sciences organizations. Validated, auditable and compliant by design.

Why Now

The industry crossed a line in April 2026

On 2 April 2026, the FDA issued a warning letter with a heading that had never appeared in an enforcement action before: Inappropriate Use of Artificial Intelligence in Pharmaceutical Manufacturing. A manufacturer had used AI agents to generate specifications, procedures and master production records. When investigators asked why process validation was never performed, the firm's answer was that its AI never told them it was required.

AI in GxP moved from the conference agenda to the enforcement record that day. The regulatory frame is hardening too: the EU's draft Annex 22 proposes that only static, locked, deterministic models be used in critical applications, with generative AI confined to non-critical uses under documented human oversight. The ISPE GAMP Guide on Artificial Intelligence now sits alongside GAMP 5 and ISO/IEC 42001 as the working framework for AI-enabled systems.

The Quality Unit's accountability cannot be delegated to an algorithm.

The Gap

Most pharma AI is still bolted on

Chatbots layered over document stores. Pilots that never leave the innovation lab. Models nobody can validate, explain or requalify. Deviations still investigated the way they were in 2010.

Bolted-on chatbots

Layered over document stores, disconnected from the systems of record.

Pilots that never launch

Proofs of concept that stay in the innovation lab and never reach a live process.

Unvalidatable models

Nobody can validate, explain or requalify them when it counts.

Manual deviations

Still investigated the way they were in 2010: reactively, manually and slowly.

The gap isn't intelligence. It's trust, traceability and evidence.

The Platform

Introducing GxMind

GxMind is AmpleLogic's purpose-built AI platform for regulated life sciences, engineered so intelligence is native to the system of record, not stitched on top of it. It isn't a copilot bolted onto a QMS. It's the AI, data and governance foundation underneath AmpleLogic's entire GxP product portfolio, built on the same low-code aPaaS that already runs quality, laboratory, manufacturing and regulatory operations for 100+ life sciences organizations worldwide.

One platform. Five layers.

Data Fabric

Unifies GxP data across quality, lab, manufacturing and regulatory, with lineage, context and ALCOA+ integrity preserved end to end. No middleware, no silos.

Models

Version-locked ML for predictive quality, anomaly detection, OOS/OOT risk, process capability and deviation recurrence. Trained on your data, in your tenant.

Copilots

Role-aware assistants inside eQMS, LIMS, MES and DMS. Conversational access to enterprise data, AI-assisted RCA, investigation drafting, SOP and dossier authoring. Every output is cited and routed for human approval.

Agents

Narrow, bounded agents for non-critical, high-volume work: triage, classification, review-by-exception prep and evidence assembly, always under a defined human checkpoint.

Trust Layer

Model registry, intended-use documentation, explainability, AI audit trail, drift monitoring, requalification triggers and validation packs.

Why Trustworthy

AI you can put in front of an inspector

Every AI capability in GxMind ships with the evidence a regulator will ask for.

Right model for the right risk

Static, locked, deterministic models where product quality, patient safety or data integrity are in scope. Generative AI stays limited to drafting, retrieval and summarization, never final approval.

Provenance on every output

Source records, model and prompt version, inputs, confidence and the named reviewer who approved it. Nothing arrives without a chain of evidence.

Explainability by default

Feature attribution for predictions. Cited source passages for every generated answer. No unexplained scores.

Human-in-the-loop by design

Approval checkpoints are configured, enforced and logged, not advisory. AI proposes, qualified people dispose.

Lifecycle, not launch

Continuous performance and drift monitoring against defined thresholds, with automatic requalification triggers and change control.

Validation-ready from day one

Intended-use statements, data lineage, independent test data, subgroup performance and prebuilt qualification documentation ship with the capability.

Your data stays yours

Tenant isolation, role-based access, and no training of shared models on customer GxP data.

Aligned to the frameworks that matter

21 CFR Part 11, EU Annex 11, GAMP 5 (2nd Edition), the ISPE GAMP Guide on Artificial Intelligence and ISO/IEC 42001, built in anticipation of EU GMP Annex 22.

Where It Shows Up

Built into how you already work

Function

Capability

Outcome

Now Open

GxMind Founding Cohort

10 places

A structured co-development programme for pharma, biotech and CDMO organizations ready to put governed AI into a live GxP process this financial year.

Manne V. Chowdary

CEO, AmpleLogic

For life sciences, the real opportunity with AI is not simply to automate more processes. It is to help people make better decisions while maintaining the transparency, accountability and controls that a regulated industry demands. That is the direction we are pursuing at AmpleLogic.

Ravi Ravuri

VP, Products & Technology, AmpleLogic

Pharma does not have an AI capability problem. It has an AI trust problem. GxMind was built for the moment the industry is in now, where the question is no longer can the model do it, but can you prove it, explain it and defend it in an inspection. That is the standard we set for every capability we ship.

Thank you

Submit an Idea, Win a Gift Card

Tell us how you would use GxMind. Our validation engine checks it instantly.

Thank you for participating!

Our team will review your entry and contact {{ form.email }} if you're selected to receive a gift card.